Case File
efta-02667901DOJ Data Set 11OtherEFTA02667901
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02667901
Pages
1
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
jeffrey E. <[email protected]>
Sent:
Tuesday, November 29, 2016 10:38 PM
To:
Jeffrey Epstein
&quo=;u.s. shareholders" of a CFC are required to file Form 5471 with thei= personal tax return, even if the CFC has no
subpart F income. Form 926 is used to report transfers ofproperty (including cash) to a foreign corporation. Si nc= a
foreign corporation will have some kind of foreign bank or financial accoun=, the U.S. shareholders who have control,
signatory authority or a financial interest, over the account must file Form TD F 90-22.1 by June 30th of the =ear after
the calendar year. If the foreign corporation's shareholders have=made an election to have the corporation treated as a
disregarded (non-corporate)en=ity for U.S. tax purposes, then the shareholders must file a Form 8865 for a foreign
partnership and a Form 8858 for a foreign disregarded entity. In or=er to make an election to be treated as a
disregarded entity, a Form 8832 must=be filed. If the foreign corporation has made an investment in any passive for=ign
investment companies, or if the foreign corporation is a PFIC, then the U.S= shareholders may be required to file a Form
8621 to report their share of t=e income of the PFIC or the gain on any dispositions of PFIC shares. If the Foreign
Corporation has any U.S.-source income, it will need to file a Form 1120-F. If it is a Foreign Sales Corporation, it will need
to file a Form 1=20-FSC. In the event of the purchase or sale of a foreign corporation, the buyer an= seller will need to
file a Form 8883, which is an Asset Allocation Statemen=. If the shareholders or the corporation rely on a treaty that
overrides a provi=ion of the IRC, a Form 8833 must be filed to reflect a Treaty Based Return Posi=ion. Depending on the
nature of thebusiness of the corporation, other forms may be required
please note
The inform=tion contained in this communication is confidential, may be attorney-c=ient privileged, may constitute
inside information, and is intended onl= for the use of the addressee. It is the property of JEE Unauthor=zed use,
disclosure or copying of this communication or any part thereo= is strictly prohibited and may be unlawful. If you have
received thisc=r>communication in error, please notify us immediately by return e-mail=or by e-mail to
<mailto:[email protected]> , and destroy this communication and all copier thereof, including all attachments.
copyright -all rights reserved =/div>
EFTA_R1_01919814
EFTA02667901
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Phone
2667901Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.